

## Millipore licenses AGR2 mAb

04 November 2010 | News

image not found or type unknown



Australian healthcare company, HealthLinx has signed a commercial agreement to license its AGR2 monoclonal antibody (mAb) to Millipore. The worldwide non-exclusive license agreement allows Millipore to market and sell the monoclonal antibody for research purposes only, with upfront fees and royalties to flow back to HealthLinx.

The second, multi-center, multi-national trial for HealthLinx's OvPlex ovarian cancer diagnostic blood test includes the testing of two additional biomarkers, one of these being the recently identified AGR2. It is anticipated that the inclusion of AGR2 in the multi-marker OvPlex panel will increase its diagnostic performance, and the ability to identify early stage cancers, and may aid in discriminating benign masses from cancer.

## Thermo Fisher forms scientific advisory board

Thermo Fisher Scientific, a global biosupplier company, has formed a Scientific Advisory Board to formalize the two-way exchange of technological information between the company and representatives, from some of the world's premiere centers of health, science and education.

"Scientific discovery is often the catalyst for change. The insight and distinct expertise of each member of our Scientific Advisory Board will be invaluable in helping us set a course for the innovation of new products and services that will meet the changing needs of our customers," said Marc N Casper, president & CEO, Thermo Fisher Scientific.